Navigation Links
An elephant tail

Use of the amino acid supplement L-arginine following a heart attack does not improve certain cardiac functions and measurements and may be associated with an increased risk of death, according to a study in the January 4 issue of JAMA.

L-arginine is a widely available dietary supplement and is publicized as having benefits for patients with hypertension, angina, heart failure and sexual dysfunction, according to background information in the article. Prior studies suggest that L-arginine has the potential to reduce vascular (blood vessel) stiffness.

Steven P. Schulman, M.D., of Johns Hopkins Medical Institutions, Baltimore, and colleagues conducted the Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) clinical trial to test whether administering L-arginine to patients following a first ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack) over a 6-month period would decrease vascular stiffness and improve ejection fraction (a measure of how much blood the left ventricle of the heart pumps out with each contraction).

The randomized, double-blind, placebo-controlled trial included 153 STEMI patients; 77 were 60 years or older. Participants were enrolled from February 2002 to June 2004. Patients were randomly assigned to receive L-arginine (goal dose of 3 g three times a day) or matching placebo for six months.

The researchers found: "The VINTAGE MI study demonstrated that 6 months of L-arginine added to standard postinfarct medications did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes. To the contrary, we noted a possible increased risk of death in older patients after infarction while taking L-arginine compared with those taking a placebo, leading to the early termination of the study. These findings have broad public health implications given the increasing availability and use of L-argin ine in patients with and without established cardiovascular diseases."

Death occurred in 6 patients (8.6 percent) in the L-arginine group died during the 6-month study period vs. none in the placebo group.

"In conclusion, L-arginine therapy should not be given to patients following a myocardial infarction. It neither alters noninvasive measures of vascular stiffness nor improves left ventricular function. L-arginine therapy in older patients with diffuse atherosclerosis may worsen clinical outcomes," the authors write.


'"/>

Source:University of Utah


Related biology news :

1. Scientists journey to southern Africa to unravel the secret world of elephant communication
2. Key to elephant conservation is in the sauce
3. Vietnam war technology could aid elephant conservation
4. Male elephants woo females with precise chemistry
5. Genetic analysis of Asian elephants in India reveals some surprises
6. WWF peeks into mysterious life of Borneos pygmy elephants
7. New study of the worlds smallest elephant
8. Drunken elephants: The marula fruit myth
9. Widespread elephant slaughter discovered in Chad
10. Serengeti patrols cut poaching of buffalo, elephants, rhinos
11. Grabbing addiction by the tail
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research ... Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity ... ... Report, forecasts that the global market is projected to reach $15,737 ... of 13% from 2016 to 2022. Omic technologies ...
(Date:1/19/2017)... and HOUSTON , ... ("NX Prenatal") today announced the formation of its ... leading clinicians and industry veterans who enhance the ... as it accelerates development of its novel prenatal ... provide medical, clinical and strategic guidance for the ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
Breaking Biology Technology: